Du sökte efter: 5-Fluorouracil

Leverantör: SIGMA-ALDRICH MICROSCOPY

Beskrivning: 5-Fluorouracil has been used to induce apoptosis in cells. It has been used as a chemosensitising agent. A potent antitumor agent that affects pyrimidine synthesis by inhibiting thymidylate synthetase, thus depleting intracellular dTTP pools. It is metabolized to ribonucleotides and deoxyribonucleotides, which can be incorporated into RNA and DNA. Treatment of cells with 5-FU leads to an accumulation of cells in S-phase and has been shown to induce p53 dependent apoptosis.

Certifikat

Artikel nummer : (8.18505.0005)

Leverantör: Merck

Beskrivning: 5-Fluorouracil för syntes, Sigma-Aldrich®

UOM: 1 * 5 g

Säkerhetsdatablad Sale

Leverantör: Apollo Scientific

Beskrivning: This pyrimidine analogue, is an antineoplastic agent.

Artikel nummer : (03738-100MG)

Leverantör: Merck

Beskrivning: Organic Standard, 5-Fluorouracil

UOM: 1 * 100 mg

Sale

Artikel nummer : (PHR1227-500MG)

Leverantör: Merck

Beskrivning: Organic Standard, Fluorouracil

UOM: 1 * 500 mg

Sale

Leverantör: Thermo Scientific

Beskrivning: 5-Fluorouracil ≥99%

Säkerhetsdatablad Certifikat

Artikel nummer : (ENZOALX480099G005)

Leverantör: ENZO LIFE SCIENCES AG

Beskrivning: Thymidylate synthetase inhibitor

UOM: 1 * 5 g

New Product Sale

Leverantör: Thermo Scientific

Beskrivning: 5-Fluorouracil 99%

Säkerhetsdatablad

Leverantör: Apollo Scientific

Beskrivning: Antineoplastic agent. Not USP. Not for drug use.

Leverantör: TCI EUROPE

Beskrivning: 5-Fluorouracil ≥99.0% (by HPLC, titration analysis)

Leverantör: Apollo Scientific

Beskrivning: Useful in the selection of orotidine-5'-phosphatedecarboxylase mutants in Saccharomycescerevisiae: Genetics, 1984, 107, 179.

Leverantör: USP

Beskrivning: USP Reference Standards are specified for use in conducting official USP–NF tests and assays. USP also provides Reference Standards specified in the Food Chemicals Codex as well as authentic substances—high-quality chemical samples—as a service to analytical, clinical, pharmaceutical and research laboratories. To confirm accuracy and reproducibility, USP Reference Standards are rigorously tested and evaluated by multiple independent laboratories including USP, commercial, regulatory, and academic labs. USP also provide publicly available, official documentary standards for pharmaceutical ingredients in the USP–NF that link directly with our primary reference standards.

Artikel nummer : (BOSSBS-8288R-A555)

Leverantör: Bioss

Beskrivning: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Sale

Artikel nummer : (BOSSBS-8288R-HRP)

Leverantör: Bioss

Beskrivning: Dihydropyrimidine dehydrogenase (DPYD) catalyzes the first rate-limiting step of the NADPH-dependent catabolism of uracil and thymine to dihydrouracil and dihydrothymine; thus, a deficiency of DPYD leads to an accumulation of uracil and thymine. Abnormal concentrations of these metabolites in bodily fluids may be the cause of neurological disease and a contraindication for treatment of cancer patients with certain pyrimidine analogs. DPYD also catalyzes the anticancer agent 5-fluorouracil (5-FU) pathway and is involved in the efficacy and toxicity of 5-FU. Variations in DPYD concentration may arise from alterations at the transcriptional level of the dihydropyrimidine dehydrogenase gene. Specifically, hypermethylation of the DPYD promoter downregulates dihydropyrimidine dehydrogenase expression. Deficient DPYD alleles may constitute a risk factor for severe toxicity following treatment with 5-FU.Involvement in disease:Defects in DPYD are the cause of dihydropyrimidine dehydrogenase deficiency (DPYD deficiency) ; also known as hereditary thymine-uraciluria or familial pyrimidinemia. DPYD deficiency is a disease characterized by persistent urinary excretion of excessive amounts of uracil, thymine and 5-hydroxymethyluracil. Patients suffering from this disease show a severe reaction to the anticancer drug 5-fluorouracil. This reaction includes stomatitis, Leukopenia, thrombocytopenia, hair loss, diarrhea, fever, marked weight loss, cerebellar ataxia, and neurologic symptoms, progressing to semicoma.

UOM: 1 * 100 µl

Sale

Leverantör: TCI EUROPE

Beskrivning: 5-Fluoro-5'-deoxyuridine (Doxifluridine) ≥98.0% (by HPLC, titration analysis)

Leverantör: Thermo Scientific

Beskrivning: 5-Fluoro-5'-deoxyuridine (Doxifluridine)